Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Here's Why Novo Nordisk (NVO) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
by Zacks Equity Research
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
by Zacks Equity Research
Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus
by Santanu Roy
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
Novo Nordisk (NVO) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day.
4 Large Drug Stocks to Hold on to Amid Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Novo Nordisk (NVO) Boasts Earnings & Price Momentum: Should You Buy?
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
by Zacks Equity Research
Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.
Novo Nordisk (NVO) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $123.46, marking a -0.36% move from the previous day.
The Zacks Analyst Blog Highlights Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health
by Zacks Equity Research
Microsoft, Novo Nordisk, United Parcel Service, Booking and Elevance Health are included in this Analyst Blog.
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
Beat the Market the Zacks Way: MediaAlpha, NVIDIA, Walmart in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $124.93, denoting a +0.06% change from the preceding trading day.
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
by Zacks Equity Research
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.